Open AccessConcurrent Sorafenib and Radiotherapy versus Radiotherapy Alone for Locally Advanced Hepatocellular Carcinoma: A Propensity-Matched Analysis
Author(s) -
Chieh-Min Liu,
BingShen Huang,
YiHao Yen,
Yuming Wang,
EngYen Huang,
Hsuan-Chih Hsu,
TiaoYuan Huang,
YaoHsu Yang,
Ji-Yen Cheng
Publication year - 2021
Publication title -
journal of hepatocellular carcinoma
Language(s) - English
Resource type - Journals
ISSN - 2253-5969
DOI - 10.2147/jhc.s323302
Subject(s) - sorafenib , medicine , radiation therapy , hepatocellular carcinoma , propensity score matching , hazard ratio , oncology , external beam radiotherapy , liver cancer , gastroenterology , confidence interval , brachytherapy
Evidence is lacking concerning the benefit of the combination of sorafenib and radiotherapy to treat advanced hepatocellular carcinoma (HCC). To date, no publication has reported the outcomes of radiotherapy alone versus concurrent therapy. We aimed to compare the effectiveness of radiotherapy alone versus concurrent radiotherapy and sorafenib for locally advanced hepatocellular carcinoma.